UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
| SEC File Number: 001-37603 |
CUSIP Number: 090655705 |
(Check one): ☐
Form 10-K ☐ Form 20-F ☐
Form 11-K ☒ Form 10-Q ☐
Form 10-D ☐ Form N-CEN ☐
Form N-CSR
For Period Ended: September 30, 2026
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
For the Transition Period Ended: Not applicable
Read Instruction (on back page) Before Preparing
Form. Please Print or Type.
Nothing in this form shall be construed to
imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the
filing checked above, identify the Item(s) to which the notification relates: Not applicable
PART I — REGISTRANT INFORMATION
Full Name of Registrant: BioRestorative
Therapies, Inc.
Former Name if Applicable: Not applicable
Address of Principal Executive Office (Street
and Number): 40 Marcus Drive, Suite 1
City, State and Zip Code: Melville, New
York 11747
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without
unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box
if appropriate)
| ☐ | (a) The reason described in reasonable detail in Part III
of this form could not be eliminated without unreasonable effort or expense; |
| ☐ | (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report
on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| ☐ | (c) The accountant’s statement or other exhibit required
by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
State below in reasonable detail the reasons why
Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed
time period.
BioRestorative Therapies, Inc. (the “Company”)
is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 (the “Q3 Form 10-Q”) within the
prescribed time period without unreasonable effort or expense, and does not expect to file the Q3 Form 10-Q within the five-day extension
period provided by Rule 12b-25(b).
As previously disclosed, on August 28, 2026 the
Company engaged Bush & Associates CPA LLC (“Bush CPA”) as its independent registered public accounting firm, replacing
CBIZ CPAs P.C. Bush CPA’s engagement includes new audits of the Company’s financial statements for the fiscal years ended
December 31, 2024 and 2025, and Bush CPA has advised the Company that its reviews of the Company’s interim financial statements
for the quarters ended June 30, 2026 and September 30, 2026 cannot be completed until those audits are complete. As a result, the Company
has not yet filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the “Q2 Form 10-Q”) and is unable
to complete the Q3 Form 10-Q within the prescribed time period or the five-day extension period.
PART IV — OTHER INFORMATION
| (1) | Name and telephone number of person to contact in regard
to this notification |
| Anna Skowron |
|
(631) |
|
760-8100 |
| (Name) |
|
(Area Code) |
|
(Telephone Number) |
| (2) | Have all other periodic reports required under Section 13
or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or
for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☐
Yes ☒ No |
The
Company has not filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as described in Part III.
| (3) | Is it anticipated that any significant change in results
of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the
subject report or portion thereof? ☒ Yes ☐
No |
If so, attach an explanation of the
anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results
cannot be made.
The Company anticipates that its results
of operations for the three and nine months ended September 30, 2026 may differ materially from the corresponding periods of 2025. On
August 7, 2026, the Company suspended orders and shipments of its biocosmeceutical product lines pending a business and regulatory review,
affecting product sales activity during the quarter. The Company also expects its results to reflect professional and advisory expenses
associated with management changes, the engagement of its new independent registered public accounting firm, and the Audit Committee investigation.
The Company is evaluating the potential financial reporting effects of former-officer contractual claims and related equity awards, the
recoverability of certain inventory and intangible assets, and borrowings under its revolving credit facility. The Company has not yet
determined whether, or to what extent, these matters will result in third-quarter charges. Because the reviews of the Company's June 30
and September 30, 2026 interim financial statements and the audits of the fiscal years ended December 31, 2024 and 2025 remain incomplete,
the Company is unable to provide a reasonable quantitative estimate of the anticipated changes at this time.
Forward-Looking Statements
This Form 12b-25 contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements regarding the completion of Bush CPA’s audits and reviews, the filing of the Q2 Form 10-Q and the Q3 Form 10-Q, and the
Company’s anticipated results of operations. These statements are based on the Company’s current expectations and are subject
to risks and uncertainties that could cause actual results to differ materially, including the risk that Bush CPA’s audits and reviews
take longer than currently anticipated, that the Company identifies additional matters requiring evaluation in the course of its financial
reporting process, and the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2025 and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation
to update any forward-looking statement, except as required by law.
BioRestorative Therapies, Inc.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its
behalf by the undersigned hereunto duly authorized.
| Date: November 16, 2026 |
By: |
/s/ Mika Grasso |
| |
Name: |
Mika Grasso |
| |
Title: |
Interim Chief Executive Officer |